Table 5.

Distribution of HLA ligands frequencies and KIR-HLA interactions in CRC cases and healthy controls.

	Healthy Controls		CRC Cases
HLA Ligands	N	%	n	%	p-Value	OR (95% CI)
Bw4	726	67.47	650	68.93	NS
Bw6	885	82.25	766	81.23	NS
Bw4/Bw4	191	17.75	177	18.77	NS
Bw4/Bw6	535	49.72	473	50.16	NS
Bw6/Bw6	350	32.53	293	31.07	NS
Bw4I80	416	38.66	361	38.28	NS
Bw4T80	402	37.36	373	39.55	NS
HLA-C1	890	82.71	752	79.75	NS
HLA-C2	725	67.38	640	67.87	NS
HLA-C1C1	351	32.62	303	32.13	NS
HLA-C1C2	539	50.09	449	47.61	NS
HLA-C2C2	186	17.29	191	20.25	NS
KIR genotypes	N	%	n	%	p-value	OR (95% CI)
KIR3DL1/KIR3DL1	738	68.59	624	66.17	NS
KIR3DL1/KIR3DS1	294	27.32	287	30.43	NS
KIR3DS1/KIR3DS1	43	4.00	32	3.39	NS
KIR2DL2/KIR2DL2	149	13.85	125	13.26	NS
KIR2DL2/KIR2DL3	341	31.69	293	31.07	NS
KIR2DL3/KIR2DL3	584	54.28	525	55.67	NS
					NS
KIR ligand associations	N	%	n	%	p-value	OR (95% CI)
KIR3DS1-Bw4I80	131	12.17	114	12.09	NS
KIR3DS1-Bw4T80	125	11.62	123	13.04	NS
KIR3DS1-Bw4	228	21.19	206	21.85	NS
KIR3DS1-Bw6	285	26.49	264	27.99	NS
KIR3DL1-Bw4I80	402	37.36	349	37.01	NS
KIR3DL1-Bw4T80	386	35.87	356	37.75	NS
KIR3DL1-Bw4	697	64.78	626	66.38	NS
KIR3DL1-Bw6	847	78.72	742	78.69	NS
KIR2DL1/HLA-C1C1	351	32.62	302	32.03	NS
KIR2DL1/HLA-C1C2	538	50.00	449	47.61	NS
KIR2DL1/HLA-C2C2	186	17.29	191	20.25	NS
KIR2DL2/HLA-C1C1	149	13.85	125	13.26	NS
KIR2DL2/HLA-C1C2	189	17.57	153	16.22	NS
KIR2DL2/HLA-C2C2	152	14.13	140	14.85	NS
KIR2DL3/HLA-C1C1	339	31.51	297	31.50	NS
KIR2DL3/HLA-C1C2	403	37.45	337	35.74	NS
KIR2DL3/HLA-C2C2	183	17.01	184	19.51	NS
KIR2DS1/HLA-C1C1	115	10.69	102	10.82	NS
KIR2DS1/HLA-C1C2	194	18.03	175	18.56	NS
KIR2DS1/HLA-C2C2	77	7.16	69	7.32	NS

NS: not significant; OR: odds ratio; CI: confidence interval.